Kazuki Nozawa, MD· @kazuki_nozawa · X·· 1 day agoScore70
Body
Phase III postMONARCH: Final OS Analysis
#ESMO26
@KalinskyKevin
Abemaciclib + fulvestrant numerically improved OS after CDK4/6i (32.1 vs 24.6 months; HR 0.80, P=0.11), without statistical significance.
PFS (HR 0.78), PFS2 (HR 0.76), and time to chemotherapy (HR 0.76) favored abemaciclib.
111 views · 4 likes · 1 repost · 0 replies
Conference abstracts
1ROmatched by Rapid oral 1: Breast cancer, advanced stage
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgSource: Kazuki Nozawa, MD · x.com